Paradox Of China Biotech And What Lies Ahead In 2023
Growth Possible Without Strong Domestic Market?
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
